SCHEMBL25309052

SCHEMBL25309052

C#Cc1ccccc1-c1cnccc1C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 16/20 0.44
▸ KDM6B O15054 9/20 0.44
▸ KDM4D Q6B0I6 6/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ KDM4A O75164 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ THRB P10828 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ SLC22A12 Q96S37 1/20 0.40
▸ MAOA P21397 1/20 0.39
▸ MAOB P27338 1/20 0.39
▸ EGLN3 Q9H6Z9 1/20 0.38
▸ KDM5B Q9UGL1 1/20 0.38
▸ LTB4R2 Q9NPC1 1/20 0.38
▸ DHODH Q02127 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31019034 1.00 KDM4C (0.44) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL25310017 0.83 KDM4E (0.49) KDM4EALDH1A1KMT2AL3MBTL1
SCHEMBL20593569 0.82 KDM4C (0.53) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL116060 0.80 KDM4C (0.55) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL28883633 0.78 KDM4C (0.49) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL30782804 0.78 KDM4C (0.49) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL29950415 0.76 KDM4C (0.61) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL6870086 0.76 MYC (0.53) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL25309450 0.75 ALDH1A1 (0.38) KDM4EMEN1ALDH1A1KMT2ADHODH
SCHEMBL25306780 0.75 POLQ (0.44) KDM4CKDM4EALDH1A1KMT2AKDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122221-A1 SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2025-04-17 — — US disclosed
EP-4464709-A1 SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2024-11-20 — — EP disclosed
WO-2023202623-A1 POLQ INHIBITOR COMPOUND AND USE THEREOF 南京再明医药有限公司 2023-10-26 — — WO disclosed
WO-2023134739-A1 SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF 南京再明医药有限公司 2023-07-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122221-A1 SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF POLRMT, POLQ, POLH KDM4C 4128/4885KDM6B 3894/4885KDM4D 4071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback